MX2011004870A - Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes. - Google Patents

Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.

Info

Publication number
MX2011004870A
MX2011004870A MX2011004870A MX2011004870A MX2011004870A MX 2011004870 A MX2011004870 A MX 2011004870A MX 2011004870 A MX2011004870 A MX 2011004870A MX 2011004870 A MX2011004870 A MX 2011004870A MX 2011004870 A MX2011004870 A MX 2011004870A
Authority
MX
Mexico
Prior art keywords
methotrexate
autoimmune disease
treating autoimmune
dhodh inhibitor
combinational therapy
Prior art date
Application number
MX2011004870A
Other languages
English (en)
Inventor
Manfred Groeppel
Johann Leban
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of MX2011004870A publication Critical patent/MX2011004870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere al tratamiento y prevención de trastornos inmunológicos e inflamatorios con un compuesto de la fórmula (I) en combinación con metotrexato, fórmula (I).
MX2011004870A 2008-11-07 2009-11-06 Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes. MX2011004870A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168668 2008-11-07
EP09162716 2009-06-15
PCT/EP2009/008057 WO2010052027A1 (en) 2008-11-07 2009-11-06 Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease

Publications (1)

Publication Number Publication Date
MX2011004870A true MX2011004870A (es) 2011-09-06

Family

ID=41571142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004870A MX2011004870A (es) 2008-11-07 2009-11-06 Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.

Country Status (13)

Country Link
US (1) US20120028985A1 (es)
EP (1) EP2362771A1 (es)
JP (1) JP2012508205A (es)
KR (1) KR20110093841A (es)
CN (1) CN102271674A (es)
AU (1) AU2009313053A1 (es)
BR (1) BRPI0921258A2 (es)
CA (1) CA2742910A1 (es)
EA (1) EA201100605A1 (es)
IL (1) IL212713A0 (es)
MX (1) MX2011004870A (es)
WO (1) WO2010052027A1 (es)
ZA (1) ZA201103337B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
UA108760C2 (uk) * 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
CA2835819A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Induction of immune tolerance using methotrexate
EP3559005A1 (en) 2016-12-21 2019-10-30 Biotheryx Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
WO2022214691A1 (en) 2021-04-09 2022-10-13 Immunic Ag Deuterated dhodh inhibitors
TW202332433A (zh) 2021-12-23 2023-08-16 德商埃慕尼克股份公司 含羧酸生物電子等排體之dhodh抑制劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1541198A1 (en) * 2003-12-05 2005-06-15 4Sc Ag Cycloalkyl compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7071355B2 (en) * 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581477B1 (en) * 2002-12-23 2009-12-02 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate

Also Published As

Publication number Publication date
ZA201103337B (en) 2012-01-25
EA201100605A1 (ru) 2012-02-28
JP2012508205A (ja) 2012-04-05
WO2010052027A1 (en) 2010-05-14
US20120028985A1 (en) 2012-02-02
IL212713A0 (en) 2011-07-31
KR20110093841A (ko) 2011-08-18
CA2742910A1 (en) 2010-05-14
CN102271674A (zh) 2011-12-07
BRPI0921258A2 (pt) 2018-10-23
AU2009313053A1 (en) 2010-05-14
EP2362771A1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
NZ598464A (en) Methods and compositions for treatment of pulmonary fibrotic disorders
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
MX2011004870A (es) Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
WO2010023422A8 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
TW200700071A (en) Novel use
MY151104A (en) Novel use
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
IN2012DN04978A (es)
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
HK1129275A1 (en) Treatment of inflammatory disorders with triazole compounds
ZA200710497B (en) Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
MX2010004814A (es) Metodos para tratar esclerodermia.
MX2010003615A (es) Tratamiento de desordenes neurologicos.
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal